Major histocompatibility class II HLA-DRα gene expression in thyrocytes:: Counter regulation by the class II transactivator and the thyroid Y box protein

被引:24
|
作者
Montani, V
Taniguchi, S
Shong, MH
Suzuki, K
Ohmori, M
Giuliani, C
Napolitano, G
Saji, M
Fiorentino, B
Reimold, AM
Ting, JPY
Kohn, LD
Singer, DS
机构
[1] NIDDKD, Cell Regulat Sect, Metab Dis Branch, NCI,NIH, Bethesda, MD 20892 USA
[2] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA
[3] Johns Hopkins Univ, Dept Surg, Baltimore, MD 21287 USA
[4] Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Publ Hlth, Dept Med, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Boston, MA 02115 USA
[7] Univ N Carolina, Lineberger Comprehens Canc Res Ctr, Chapel Hill, NC 27599 USA
关键词
D O I
10.1210/en.139.1.280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aberrant expression of major histocompatibility complex (MHC) class II proteins on thyrocytes; which is associated with autoimmune thyroid disease, is mimicked by gamma-interferon (gamma-IFN). To define elements and factors that regulate class II gene expression in thyrocytes and that might be involved in aberrant expression, we have studied gamma-IFN-induced HLA-DR alpha gene expression in rat FRTL-5 thyroid cells. The present report shows that class II expression in FRTL-5 thyrocytes is positively regulated by the class II transactivator (CIITA), and that CIITA mimics the action of gamma-IFN. Thus, as is the case for gamma-IFN, several distinct and highly conserved elements on the 5'-flanking region of the HLA-DR alpha gene, the S, X-1, X-2, and Y boxes between -137 to -65 bp, are required for class II gene expression induced by pCIITA transfection in FRTL-5 thyroid cells. CIITA and gamma-IFN do not cause additive increases in HLA-DR alpha gene expression in FRTL-5 cells, consistent with the possibility that CIITA is an intermediate factor in the gamma-IFN pathway to increased class II gene expression. Additionally, gamma-IFN treatment of FRTL-5 cells induces an endogenous CIITA transcript; pCIITA transfection mimics the ability of gamma-IFN treatment of FRTL-5 thyroid cells to increase the formation of a specific and novel protein/DNA complex containing CBP, a coactivator of CRE binding proteins important for cAMP-induced gene expression; and the action of both gamma-IFN and CIITA to increase class II gene expression and increase complex formation is reduced by cotransfection of a thyroid Y box protein, which suppresses MHC class I gene expression in FRTL-5 thyroid cells and is a homolog of human YB-1, which suppresses MHC class II expression in human glioma cells. We conclude that CIITA and TSH receptor suppressor element binding protein-1 are components of the gamma-IFN-regulated transduction system which, respectively, increase or decrease class II gene expression in thyrocytes and may, therefore, be involved in aberrant class II expression associated with autoimmune thyroid disease.
引用
收藏
页码:280 / 289
页数:10
相关论文
共 50 条
  • [31] Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA)
    Takamura, Y
    Ikeda, H
    Kanaseki, T
    Toyota, M
    Tokino, T
    Imai, K
    Houkin, K
    Sato, N
    GLIA, 2004, 45 (04) : 392 - 405
  • [32] POLYMORPHISM AND REGULATION OF HLA CLASS-II GENES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX
    MACH, B
    GORSKI, J
    ROLLINI, P
    BERTE, C
    AMALDI, I
    BERDOZ, J
    UCLA, C
    COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1986, 51 : 67 - 74
  • [33] The class II transactivator requires brahma-related gene 1 to activate transcription of major histocompatibility complex class II genes
    Mudhasani, R
    Fontes, JD
    MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (14) : 5019 - 5026
  • [34] Novel mechanisms of class II major histocompatibility complex gene regulation
    Radosevich, M
    Ono, SJ
    IMMUNOLOGIC RESEARCH, 2003, 27 (01) : 85 - 105
  • [35] Major histocompatibility complex class II deficiency: A disease of gene regulation
    Steimle, V
    Reith, W
    Mach, B
    ADVANCES IN IMMUNOLOGY, VOL 61, 1996, 61 : 327 - 340
  • [36] Novel mechanisms of class II major histocompatibility complex gene regulation
    Michael Radosevich
    Santa Jeremy Ono
    Immunologic Research, 2003, 27 : 85 - 105
  • [37] PML promotes MHC class II gene expression by stabilizing the class II transactivator
    Ulbricht, Tobias
    Alzrigat, Mohammad
    Horch, Almut
    Reuter, Nina
    von Mikecz, Anna
    Steimle, Viktor
    Schmitt, Eberhard
    Kraemer, Oliver H.
    Stamminger, Thomas
    Hemmerich, Peter
    JOURNAL OF CELL BIOLOGY, 2012, 199 (01): : 49 - 63
  • [38] Major histocompatibility complex class II transactivator gene polymorphism: associations with Lofgren's syndrome
    Grunewald, J.
    Idali, F.
    Kockum, I.
    Seddighzadeh, M.
    Nisell, M.
    Eklund, A.
    Padyukov, L.
    TISSUE ANTIGENS, 2010, 76 (02): : 96 - 101
  • [39] Interleukin-27 upregulates major histocompatibility complex class II expression in primary human endothelial cells through induction of major histocompatibility complex class II transactivator
    Feng, Xiao Ming
    Chen, Xiao Li
    Liu, Na
    Chen, Zhong
    Zhou, Yu Ling
    Han, Zhi Bo
    Zhang, Lei
    Han, Zhong Chao
    HUMAN IMMUNOLOGY, 2007, 68 (12) : 965 - 972
  • [40] Regulation of major histocompatibility (MHC) class II human leukocyte antigen-DRα gene expression in thyrocytes by single strand binding protein-1, a transcription factor that also regulates thyrotropin receptor and MHC class I gene expression
    Balducci-Silano, PL
    Suzuki, K
    Ohta, M
    Saito, J
    Ohmori, M
    Montani, V
    Napolitano, G
    Shong, M
    Taniguchi, SI
    Pietrarelli, M
    Lavaroni, S
    Mori, A
    Singer, DS
    Kohn, LD
    ENDOCRINOLOGY, 1998, 139 (05) : 2300 - 2313